“We believe this data-driven collaboration supporting patient screening for clinical trials and the development of data-driven early detection algorithms for pancreatic patients will help us in our quest to improve cancer patient outcomes."
CUPERTINO, Calif. (PRWEB) April 17, 2018
TransMed announced today a collaboration with HonorHealth that will accelerate patient access to clinical trials through advanced predictive modeling tools and patient screening technologies. This innovative technology offers immediate benefit for HonorHealth patients and team of oncologists and researchers including the HonorHealth Research Institute’s Early Detection Program of pancreatic, breast, ovarian and colorectal cancers.
Daniel D. Von Hoff, MD, Chief Scientific Officer of the HonorHealth Research Institute states, “We believe that this data-driven collaboration supporting patient screening for clinical trials and the development of data-driven early detection algorithms for pancreatic patients will help us in our quest to improve cancer patient outcomes.”
“We are continuing to expand our footprint in cancer clinical research through precision medicine technology and innovation,” according to Kiran Avancha, PhD, Chief Operating Officer of the HonorHealth Research Institute. “Our ability to analyze phenotype and genotype data of a patient by deploying this technology and by integrating it with our own predictive modeling will be instrumental in helping patients fight cancer by enrolling them on a matching clinical trial.”
According to Carla Balch, TransMed President and Chief Operating Officer, “The TransMed team is delighted to collaborate with the HonorHealth Research Institute to accelerate patient access to clinical trials. Our mission at TransMed is to ensure every patient has access to the best treatment option, which is often a clinical trial. We are especially proud of the advanced scientific work we’ve done regarding Pancreatic Cancer. Achieving consistent and sustainable long-term success in clinical research increasingly depends on effective use of real-world evidence. Through this collaboration, research teams can quickly and easily identify which trials would be a fit for patients, ensuring no patient is overlooked for a clinical trial option. We are thrilled to serve the patients of HonorHealth.”
About Honor Health (https://www.honorhealth.com)
HonorHealth is a non-profit health system serving an area of 1.6 million people in the greater Phoenix area. The network encompasses five acute-care hospitals, an extensive medical group, outpatient surgery centers, a cancer care network, clinical research, medical education, a foundation and community services with approximately 11,500 employees, 3,700 affiliated physicians and 3,100 volunteers. HonorHealth was formed by a merger between Scottsdale Healthcare and John C. Lincoln Health Network. HonorHealth’s mission is to improve the health and well-being of those we serve. Learn more at HonorHealth.com.
About TransMed Systems, Inc. (http://www.xbtransmed.com)
TransMed Systems provides Precision Medicine and Clinical Research technology solutions that facilitate the exploration, reporting and analysis of clinical, molecular and healthcare operational data. TransMed unlocks the potential of the healthcare repository by tightly integrating analytics with aggregated data, thus providing sophisticated matching of potential clinical trial patients to complex clinical trials to accelerate patient enrollment. Our solutions are used by clinical research teams in Life Science companies, CROs and oncology service lines in community oncology, integrated delivery networks, health system and academic medical centers.